This site uses cookies, including third-party cookies, that help us to provide and improve our services. Read More

Urinary Tract Infection Treatment Market

Over 45% Urinary Tract Infection Treatment Covered by Quinolones Antibiotic: Fact.MR Study

Published : 18 Jan 2022 Industry: Healthcare

Fact.MR’s urinary tract infection treatment market report forecasts 2.1% CAGR across the 2021-2031 assessment period. As per the report by Fact.MR, a market research and competitive intelligence provider, the market is poised to be valued at around US$ 12.9 Bn by 2031. Growth is due to increasing prevalence of urinary tract infection, unhygienic lifestyles, antibiotic resistance, recurrence of complicated UTIs, and urinary catheterization. All these factors have significantly increased the number of hospital visits for UTI treatment per year.

Urinary tract infection is amongst the most common bacterial infections that affect millions of people worldwide. Recurrent urinary tract infection is a major health issue in females across the globe. Increasing geriatric population is another factor that is expected to boost demand for UTI treatment as the elderly population is at high risk of contracting the same.

As per Medscape reported data in 2020, UTIs in women are very common; approximately 25-40% of women in the United States aged 20-40 years have had a UTI. UTIs account for over 6 million patient visits to physicians per year in the United States. Approximately 20% of those visits are to hospitals. It is estimated that 150 million UTIs occur yearly on a global basis.

Companies are expanding indications for existing antibiotic drugs and changing the administration route of these drugs to increase sales in terms of value and volume. It is easy for physicians to start intravenous therapy in hospitals if a drug is available in both forms: oral and intravenous. Hence, this different route of administration with different dosage is highly adopted by doctors, thereby providing lucrative opportunities to generate more revenue for market players.

Key Takeaways from Market Study

  • By drug class, quinolones hold a high share of 45.7% in 2021, and the segment is set to expand at 2.5% CAGR over the forecast period of 2021 to 2031.
  • By indication, uncomplicated UTI is valued at US$ 8 Bn in 2021, and is expected to increase to a value of US$ 9.7 Bn by 2031, indicating highest demand due to high prevalence of the disease.
  • By distribution channel, retail pharmacies account for 55.8% market share.
  • Europe held the largest share of 33.7% in the global urinary tract infection treatment market in 2021, due to major technological advancements and high percent of geriatric population who are more prone to UTIs.

“Increasing per capita consumption of antibiotics, rising incidence of UTI, and innovative drug delivery strategies are prompting healthcare providers to incorporate new treatment regimens for urinary tract infection,” says a Fact.MR analyst.

Competitive Landscape

Key players such as Bayer AG and Pfizer, amongst others, are focusing on collaboration and research activities for approvals

  • Bayer announced the initiation of the FIONA study, a multicenter, randomized, double-blind, placebo-controlled Phase III study, of finerenone for the treatment of pediatric patients with chronic kidney disease (CKD) and severely increased proteinuria (2021).
  • Pfizer and LianBio announced a strategic collaboration to expand the development of novel therapeutics in Greater China (2020).

Similarly key developments of other companies such as GlaxoSmithKline Pharmaceuticals Ltd., Pfizer, Allergan Plc, Almirall SA, Bristol-Myers Squibb, and Merck & Co., Inc. have been tracked in the study by Fact.MR.

More Valuable Insights Available

Fact.MR, in its new offering, presents an unbiased analysis of the urinary tract infection treatment market, presenting historical demand data (2016-2020) and forecast statistics for the period of 2021-2031.

The study divulges essential insights on the market on the basis of drug class (penicillin & combinations, quinolones, cephalosporin, aminoglycoside antibiotics, sulphonamides (sulfamethoxazole + trimethoprim), azoles and amphotericin b, tetracycline (doxycycline), nitrofurans (nitrofurantoin), others), indication (complicated UTI, uncomplicated UTI), and by distribution channel (hospital pharmacies, gynecology and urology clinics, drug stores, retail pharmacies, online drug stores), across seven major regions (North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa).

Fact.MR’s Domain Knowledge on Healthcare

Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support - encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.

For more information, refer to our market research report or contact the PR author.

Shambhu Nath Jha

Fact.MR

Sr. Consultant - Healthcare

E-mail: shambhu@factmr.com

- Request for More Information -

Urinary Tract Infection Treatment Market

Urinary Tract Infection Treatment Market
*
*
*
*
*
*

I would like to request for

Urinary Tract Infection Treatment Market Analysis by Drug Class (Penicillin and Combinations, Quinolones, Cephalosporin, Aminoglycoside Antibiotics, Sulphonamides), by Indication (Complicated UTI, Uncomplicated UTI), by Distribution Channel & Regional Forecast 2021-2031